Universal proposal strategies of anti-HPV vaccination for adolescents: comparative analysis between school-based and clinic immunization programs.




INTRODUCTION – A promising approach in order to increase adolescents’ adhesion to anti-HPV immunization is the administration of the vaccines within educational institutes. Taranto Local Health Unit experimented two different strategies of universal proposal for the vaccination of 12 year olds: the first is in the traditional call from the clinic while the second involves schools within the territory. The objective of the study is to evaluate the results of these strategies on different genders and different urban contests in order to identify an effective process that can lead to optimal coverage.

METHODS – In order to estimate the number of anti-HPV doses administrated to the adolescents of the 2003 cohort, data from the Puglia region’s computerized vaccine registry have been used. Coverages of the anti-HPV vaccinations have been analyzed, dividing these by gender, proposal strategy and district size. Analyses were performed by using STATA SE 14.

RESULTS – The multiple logistic regression underlines that female sex (OR = 3.2; p < 0.01), living in a small community  (OR = 1.3; p < 0.01) and school vaccination program (OR = 2; p < 0.01) increase the probability of completing the anti-HPV vaccination cycle in adolescents. The comparative evaluation of the anti-HPV coverage based on proposal strategies, shows that the school vaccination leads to significantly better results compared to the clinic vaccination, for all the groups taken into account (overall 72.3% vs 55.6%)

CONCLUSIONS – The involvement of educational institutes can define a winning organization model in order to obtain a bigger adhesion of adolescents to immunization programs, especially for the male sex and in bigger communities.



Centers for Disease Control and Prevention. What is HPV? Available at: http://www.cdc.gov/hpv/parents/whatishpv.html . Last Accessed: 2016 Nov 14.

Bruni L, Diaz M, Castellsague X et al. Cervical human papillomavirus prevalence in 5 continents: meta-analysis of 1 million women with normal cytological findings. J Infect Dis 2010; 202 (12) : 1789-99.

HPV and cervical cancer in the 2007 report. Vaccine 2007, 25 Suppl 3: C1-230, C1-230.

Arbyn M, Castellsague X, deSanjose S, Bruni L, Saraiya M, Bray F, et al: Worldwide burden of cervical cancer in 2008. Ann Oncol 2011, 22 : 2675-2686.

Kjaer SK, Tran TN, Sparen P, Tryggvadottir L, Munk C, Dasbach E, et al: The burden of genital warts: a study of nearly 70,000 women from the general female population in the 4 Nordic countries. J Infect Dis 2007, 196 : 1447-1454.

Roteli-Martins CM, de Carvalho NS, Naud P, Teixeira J, Borba P, Derchain S, et al: Prevalence of human papillomavirus infection and associated risk factors in young women in Brazil, Canada, and the United States: a multicenter cross-sectional study. Int J Gynecol Pathol 2011, 30 : 173-184.

Ting J, Kruzikas DT, Smith JS: A global review of age-specific and overall prevalence of cervical lesions. Int J Gynecol Cancer 2010, 20 : 1244-1249.

Arbyn M, Castellsague X, de Sanjose S, Bruni L, Saraiya M, Bray F, et al. Worldwide burden of cervical cancer in 2008. Annals of oncology. 2011; 22 (12) : 2675–86.

Anic GM, Giuliano AR: Genital HPV infection and related lesions in men. Prev Med. 2011 Oct; 53 Suppl 1: S36-41.

Marty R, Roze S, Bresse X, Largeron N, Smith-Palmer J. Estimating the clinical benefits of vaccinating boys and girls against HPV-related diseases in Europe. BMC Cancer. 2013 Jan 8; 13:10.

Jit M, Brisson M, Portnoy A, Hutubessy R. Cost-effectiveness of female human papillomavirus vaccination in 179 countries: a PRIME modelling study. The Lancet Global health. 2014; 2 (7) : e 406–14.

Bonanni P, Levi M, Latham NB, et al. An overview on the implementation of HPV vaccination in Europe. Hum Vaccin. 2011 ; 7 Suppl : 128-35.

Giuliano, A., Palefsky, J., Goldstone, S., Moreira, E., Jr, Penny, M., Aranda, C. et al. (2011) Efficacy of quadrivalent HPV vaccine against HPV infection and disease in males. N Engl J Med 364 : 401–411.

CDC. HPV and Men - Fact Sheet. Available at: http://www.cdc.gov/std/hpv/stdfact-hpv-and-men.htm . Last accessed: 2016 Dec 2.

World Health Organization. Human papillomavirus vaccines. WHO position paper. Releve epidemiologique hebdomadaire / Section d'hygiene du Secretariat de la Societe des Nations. Weekly epidemiological record / Health Section of the Secretariat of the League of Nations. 2009; 84 (15) : 118–31.

Wigle J, Fontenot HB, Zimet GD. Global Delivery of Human Papillomavirus Vaccines. Pediatr Clin North Am. 2016 Feb; 63 (1) : 81-95.

Centers for Disease Control and Prevention. Recommendations on the use of quadrivalent human papillomavirus vaccine in males–Advisory Committee on Immunization Practices (ACIP), 2011. Available at: http://www.cdc.gov/mmwr/preview/mmwrhtml/mm6050a3.htm . Last Accessed 2016 Nov 21.

Public Health Agency of Canada. Update on human papillomavirus (HPV) vaccines: recommendations. Available at: http://www.phac-aspc.gc.ca/publicat/ccdrrmtc/12vol38/acs-dcc-1/index-eng.php#a5 . Last Accessed 2016 Nov 24.

Australian Cancer Research Foundation. World-first HPV vaccination plan will protect young Australian men from cancer. Available at: http://acrf.com.au/2012/world-firsthpv-vaccination-plan-will-protect-young-australian-men-from-cancer/ . Last Accessed 2016 Dec 6.

Zuccotti GV, Mameli C. L’infezione da HPV nel maschio. Rivista di Immunologia e allergologia pediatrica 2014 Apr; 39-44.

ECDC. Recommended immunisations for human papillomavirus infection. Available at: http://vaccine-schedule.ecdc.europa.eu/Pages/Scheduler.aspx. . Last Accessed: 2016 Dec 6.

Kim JJ, Goldie SJ. Health and economic implications of HPV vaccination in the United States. N Engl J Med. 2008 Aug 21; 359 (8) : 821-32.

Bonanni P, Bechini A, Donato R, Capei R, Sacco C, Levi M, Boccalini S. Human papilloma virus vaccination: impact and recommendations across the world. Ther Adv Vaccines. 2015 Jan; 3 (1) : 3-12.

Brabin L, Roberts SA, Stretch R, et al. Uptake of first two doses of human papillomavirus vaccine by adolescent schoolgirls in Manchester: prospective cohort study. BMJ. 2008; 336 (7652): 1056–1058.

Stretch R. Implementing a school-based HPV vaccination programme. Nurs Times. 2008; 104 (48): 30–33.

Reeve C, De La Rue S, Pashen D, et al. School-based vaccinations delivered by general practice in rural north Queensland: an evaluation of a new human papilloma virus vaccination program. Commun Dis Intell. 2008; 32 (1): 94–98.

Watson M, Shaw D, Molchanoff L, McInnes C. Challenges, lessons learned and results following the implementation of a human papilloma virus school vaccination program in south Australia. Aust N Z J Public Health. 2009; 33(4): 365–370.

Brotherton JM, Deeks SL, Campbell-Lloyd S, et al. Interim estimates of human papillomavirus vaccination coverage in the school-based program in Australia. Commun Dis Intell. 2008; 32 (4): 457–461.

Cawley J, Hull HF, Rousculp MD. Strategies for implementing school-located influenza vaccination of children: a systematic literature review. J Sch Health. 2010; 80(4) : 167–175.

Humiston SG, Rosenthal SL. Challenges to vaccinating adolescents: vaccine implementation issues. Pediatr Infect Dis J. 2005; 24 (6 Suppl): S134–S140.

Lindley MC, Boyer-Chu L, Fishbein DB, et al. The role of schools in strengthening delivery of new adolescent vaccinations. Pediatrics. 2008; 121 (Suppl 1): S46–S54

Elfström KM, Dillner J, Arnheim-Dahlström L. Organization and quality of HPV vaccination programs in Europe. Vaccine. 2015 Mar 30; 33(14): 1673-81.

Hayes KA, Entzel P, Berger W, et al. Early lessons learned from extramural school programs that offer HPV vaccine. J Sch Health. 2013; 83(2):119–126.

Reiter PL, Cates JR, McRee A-L, Gottlieb SL, Shafer A, Smith JS, et al. Statewide HPV vaccine initiation among adolescent females in North Carolina. Sexually Transmitted Diseases 2010; 37(9): 549–56.

Staras SAS, Vadaparampil ST, Haderxhanaj LT, Shenkman EA. Disparities in human papillomavirus vaccine series initiation among adolescent girls enrolled in Florida Medicaid programs: 2006–2008. Journal of Adolescent Health 2010; 47(4): 381–8.

Rand CM, Schaffer SJ, Humiston SG, Albertin CS, Shone LP, Heintz EV, et al. Patient—provider communication and human papillomavirus vaccine acceptance. Clinical Pediatrics 2011; 50(2): 106–13.

Italian High Council of Health - Session XLVI, United Sections 1st and 2nd . Meeting on 11/01/2007. Available at: http://www.salute.gov.it/imgs/c_17_pubblicazioni_600_allegato.pdf . Last accessed: 2016 Nov 15.

Official Bulletin of the Puglia Region 47/2008. Council resolution No. 245.

Official Bulletin of the Puglia Region 74/2014. Council resolution No. 958.

National collective agreement 23/03/2005 – Integrated text 29/07/2009. Available at: http://www.sisac.info/aree/www.sisac.info/resources/MEDICINA_GENERALE/ACN%2029%20luglio%202009/ACN_29_luglio_2009.pdf . Last accessed: 2016 Nov 15.

Paul P, Fabio A. Literature review of HPV vaccine delivery strategies: considerations for school- and non-school based immunization program. Vaccine. 2014 Jan 9; 32 (3): 320-6.

Lindley MC, Jeyarajah J, Yankey D, Curtis CR, Markowitz LE, Stokley S. Comparing human papillomavirus vaccine knowledge and intentions among parents of boys and girls. Hum Vaccin Immunother. 2016 Jun 2; 12(6):1519-27.

Newman PA, Logie CH, Doukas N, Asakura K. HPV vaccine acceptability among men: a systematic review and meta-analysis. Sex Transm Infect 2013; 89: 568–574.

Gilkey MB, Calo WA, Moss JL, Shah PD, Marciniak MW, Brewer NT. Provider communication and HPV vaccination: The impact of recommendation quality. Vaccine. 2016 Feb 24; 34(9): 1187-92.